Enanta Pharmaceuticals Inc. (ENTA)’s Financial Results Comparing With Ionis Pharmaceuticals Inc. (NASDAQ:IONS)

We will be contrasting the differences between Enanta Pharmaceuticals Inc. (NASDAQ:ENTA) and Ionis Pharmaceuticals Inc. (NASDAQ:IONS) as far as profitability, analyst recommendations, risk, institutional ownership, dividends, earnings and valuation are concerned. The two businesses are rivals in the Biotechnology industry.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Enanta Pharmaceuticals Inc. 238.40M 7.52 86.27M 4.13 25.17
Ionis Pharmaceuticals Inc. 599.67M 19.53 276.87M 0.51 137.95

Table 1 shows gross revenue, earnings per share and valuation of the two companies. Ionis Pharmaceuticals Inc. appears to has lower earnings, but higher revenue than Enanta Pharmaceuticals Inc. When company has lower P/E means it is more affordable than its counterpart presently. Enanta Pharmaceuticals Inc. is presently more affordable than Ionis Pharmaceuticals Inc., because it’s trading at a lower P/E ratio.

Profitability

Table 2 hightlights the return on equity, return on assets and net margins of the two companies.

Net Margins Return on Equity Return on Assets
Enanta Pharmaceuticals Inc. 36.19% 22.8% 21.5%
Ionis Pharmaceuticals Inc. 46.17% -31.1% -8.7%

Risk and Volatility

Enanta Pharmaceuticals Inc. is 41.00% more volatile than Standard & Poor’s 500 due to its 1.41 beta. Competitively, Ionis Pharmaceuticals Inc.’s beta is 2.39 which is 139.00% more volatile than Standard & Poor’s 500.

Liquidity

The Current Ratio of Enanta Pharmaceuticals Inc. is 18.7 while its Quick Ratio stands at 18.7. The Current Ratio of rival Ionis Pharmaceuticals Inc. is 8 and its Quick Ratio is has 8. Enanta Pharmaceuticals Inc. is better equipped to clear short and long-term obligations than Ionis Pharmaceuticals Inc.

Analyst Recommendations

The Recommendations and Ratings for Enanta Pharmaceuticals Inc. and Ionis Pharmaceuticals Inc. are featured in the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Enanta Pharmaceuticals Inc. 0 0 1 3.00
Ionis Pharmaceuticals Inc. 0 2 1 2.33

Enanta Pharmaceuticals Inc.’s average target price is $80, while its potential downside is -13.23%. Competitively the average target price of Ionis Pharmaceuticals Inc. is $68.33, which is potential -19.24% downside. The data from earlier shows that analysts belief suggest that Enanta Pharmaceuticals Inc. seems more appealing than Ionis Pharmaceuticals Inc.

Institutional & Insider Ownership

Enanta Pharmaceuticals Inc. and Ionis Pharmaceuticals Inc. has shares held by institutional investors as follows: 86.8% and 89.1%. 5.6% are Enanta Pharmaceuticals Inc.’s share held by insiders. Competitively, Ionis Pharmaceuticals Inc. has 0.2% of it’s share held by insiders.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Enanta Pharmaceuticals Inc. 3.18% 30.74% 22.87% 13.91% 33.26% 46.62%
Ionis Pharmaceuticals Inc. 14.3% 21.53% 21.62% 52.61% 33.45% 30.39%

For the past year Enanta Pharmaceuticals Inc.’s stock price has bigger growth than Ionis Pharmaceuticals Inc.

Enanta Pharmaceuticals, Inc., a research and development-focused biotechnology company focuses on discovering and developing small molecule drugs for the treatment of viral infections and liver diseases. The companyÂ’s research and development focuses on four disease targets: Hepatitis C virus (HCV), Hepatitis B virus (HBV), Non-alcoholic Steatohepatitis (NASH), and Respiratory Syncytial Virus (RSV). Its lead product is paritaprevir, a protease inhibitor designed for use against HCV. The company also develops HCV protease inhibitor in phase III development with AbbVie, as well as a HCV program using a different class of molecules known as cyclophilin inhibitors. In addition, it has a program in non-alcoholic steatohepatitis; and discovers programs in other areas of viral infection and liver disease. Enanta Pharmaceuticals, Inc. has a collaborative development and license agreement with AbbVie to develop and commercialize HCV NS3 and NS3/4A protease inhibitors. The company was founded in 1995 and is headquartered in Watertown, Massachusetts.

Ionis Pharmaceuticals, Inc. engages in discovering and developing RNA-targeted therapeutics. The company markets SPINRAZA, an antisense drug for spinal muscular atrophy in pediatric and adult patients; and Kynamro an oligonucleotide inhibitor for use in patients with homozygous familial hypercholesterolemia to reduce low density lipoprotein-cholesterol, apolipoprotein B, total cholesterol, and non-high density lipoprotein-cholesterol, and as an adjunct to lipid lowering medications and diet. Its drugs in Phase III development include volanesorsen for the treatment of patients with familial chylomicronemia syndrome and familial partial lipodystrophy; and IONIS-TTRRx, an antisense drug to treat all forms of transthyretin amyloidosis. The company also develops IONIS-HTTRx, an antisense drug to treat patients with Huntington's disease; IONIS-SOD1Rx, an antisense drug to treat patients with an inherited form of amyotrophic lateral sclerosis; AKCEA-ANGPTL3-LRx, a LICA drug for treating multiple lipid disorders or mixed dyslipidemias; IONIS-PKKRx, an antisense drug that treats patients with hereditary angioedema; IONIS-FXIRx, an antisense drug for the treatment of thrombosis; AKCEA-APO(a)-LRx, a LICA drug that reduces apolipoprotein(a) in the liver to offer a direct approach for reducing lipoprotein(a); and AKCEA-APOCIII-LRx, an antisense drug for cardiometabolic disease. In addition, it develops IONIS-AR-2.5Rx, an antisense drug that treats patients with prostate cancer; IONIS-STAT3-2.5Rx, a cancer drug; AKCEA-ANGPTL3-LRx, a LICA drug to treat multiple lipid disorders; IONIS-GCGRRx, an antisense drug to treat patients with type 2 diabetes; and IONIS-DGAT2Rx, an antisense drug to treat patients with liver disease. The company was formerly known as Isis Pharmaceuticals, Inc. and changed its name to Ionis Pharmaceuticals, Inc. in December 2015. Ionis Pharmaceuticals, Inc. was founded in 1989 and is headquartered in Carlsbad, California.